Akademik Veri Yönetim Sistemi
42. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 25 - 30 Kasım 2025, ss.224-225, (Özet Bildiri)
Introduction: Monocyte-to-HDL Cholesterol Ratio (MHR), Visceral Adiposity Index (VAI), Plasma Atherogenic Index (PAI), and Cardiometabolic Index (CMI) are considered biomarkers for the diagnosis and risk assessment of inflammatory and metabolic diseases. This study aimed to investigate the roles of MHR, VAI, AIP, and CMI indices in determining hepatic inflammation and fibrosis in patients with MASLD across Turkey. Methods: This retrospective, cross-sectional national study was conducted with individuals with at least one cardiometabolic risk factor from 44 internal medicine clinics in 31 provinces representing all statistical regions of Turkey. Demographic characteristics, comorbidities, and laboratory parameters of participants were recorded. MHR, VAI, AIP, and CMI indices, and FIB-4 scores were calculated. Results: A total of 14,322 patients were included, and baseline characteristics, comorbid conditions, and index scores are given in Table 1. Of patients, 10,836 (75.66%) were diagnosed with MASLD, and VAI, PAI, and CMI were significantly higher in individuals with MASLD, while MHR did not show a significant difference. Among MASLD patients, 1,214 (11.2%) were in the high Fib-4 score group. All indices were found to be similar between high and low Fib-4 score groups (p>0.05, Table 2). Conclusion: The results of our study briefly revealed that while VAI, PAI, and CMI were significantly higher in MASLD patients, no such association was observed between Fib-4 score and lipid indices. Results indicate that while novel lipid indices could be used in MASLD screening and risk assessment, such indices have no role in predicting liver fibrosis.